ArticleFrontiers in pharmacology2021

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers.

Min Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.